Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

BACKGROUND: Tyrosine-kinase inhibitors (TKIs) have become the cornerstone treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations. The counterpart of these drugs is the financial burden that they impose, which often creates a barrier for accessing treatment in deve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Arrieta, Oscar, Catalán, Rodrigo, Guzmán-Vazquez, Silvia, Barrón, Feliciano, Lara-Mejía, Luis, Soto-Molina, Herman, Ramos-Ramírez, Maritza, Flores-Estrada, Diana, de la Garza, Jaime
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465360/
https://ncbi.nlm.nih.gov/pubmed/32873256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07329-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados